STELLAR-311: a randomized phase II/III study of zanzalintinib versus everolimus in advanced neuroendocrine tumors.
Jennifer A Chan, Jonathan R Strosberg, Changhoon Yoo...
https://pubmed.ncbi.nlm.nih.gov/42803451/Actively Recruiting
Led by Exelixis · Updated on 2026-10-30
440
Participants Needed
135
Research Sites
N/A
Total Duration
Researchers are evaluating the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced, or metastatic neuroendocrine tumors. This Phase 23, randomized, open-label study focuses on participants with well-differentiated Grade 1, 2, or 3 neuroendocrine tumors of pancreatic or extra-pancreatic origin who have experienced disease progression after prior therapies. Participants will be randomly assigned to receive either zanzalintinib or everolimus as oral tablets taken once daily. The study uses a crossover design, allowing participants to switch treatments during the trial. Tumor tissue samples are collected if available, and imaging assessments using CT or MRI scans will be performed to evaluate disease status. During the study, participants will be closely monitored for progression-free survival up to 48 months, along with secondary outcomes including overall survival, response rates, and quality of life measures. Safety is assessed by tracking adverse events over the trial period. Participants are expected to attend regular visits for assessments and evaluations throughout the duration of the study, which is planned to continue until June 2029.
CONDITIONS
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
E
Exelixis Clinical Trials
B
Backup or International
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Exelixis
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Zanzalintinib | Everolimus (Trial Arm) | Everolimus (Standard of Care) |
|---|---|---|---|
| What it is | An investigational oral multi‑kinase inhibitor targeting TAM kinases (TYRO3, AXL, MER), MET and VEGFR being evaluated in this randomized phase 2/3 trial. | An active oral mammalian target of rapamycin (mTOR) inhibitor serving as the comparator arm in this randomized trial. | An approved mTOR inhibitor recognised as a current standard systemic therapy for progressive well‑differentiated neuroendocrine tumors. |
| Role in the trial | Investigational therapy randomly assigned to participants. | Active comparator therapy randomly assigned to participants. | Represents usual systemic treatment available outside the trial. |
| Primary use | Experimental treatment under investigation for progressive NETs. | Established systemic therapy evaluated within trial for efficacy comparison. | Used routinely as systemic therapy for progressive well‑differentiated NETs. |
| How it is given or performed | Oral administration once daily, per trial protocol. | Oral administration once daily, per trial protocol. | Administered orally once daily in routine practice. |
| Evidence status | Efficacy and safety are being evaluated; early data show encouraging activity in solid tumors. | Efficacy established in prior studies; evaluated head‑to‑head in current trial. | Proven to prolong progression‑free survival in prior clinical trials for NETs. |
| Important limitations | Safety and efficacy not yet confirmed; benefit over everolimus remains unknown until trial results. | Efficacy compared directly only within trial duration; longer‑term outcomes to be assessed. | Current standard but overall survival benefit modest and resistance occurs over time. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 48 months
Participants receive either zanzalintinib or everolimus as oral tablets once daily under a randomized crossover design.
Regular visits for assessments and imaging
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jennifer A Chan, Jonathan R Strosberg, Changhoon Yoo...
https://pubmed.ncbi.nlm.nih.gov/42803451/Exelixis
Lead Sponsor